LUNG vs TECH · rev $83.8M vs P/E 65, rev $1.22B
Pulmonx Corp (LUNG) versus Bio-Techne Corp (TECH) — a side-by-side from cached financials, not a winner call.
Pulmonx Corp (LUNG) is a medical devices company listed on US.
Bio-Techne Corp (TECH) is a biotechnology company listed on US.
Latest reported LUNG revenue for 2024-12-31 was $83.8M. Net income was -$56.4M. Revenue was up 22.0% from 2023-12-31 to 2024-12-31. LUNG currently screens at market cap $111.9M.
Latest reported TECH revenue for 2025-06-30 was $1.22B. Net income was $73.4M. Revenue was up 5.2% from 2024-06-30 to 2025-06-30. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
LUNG currently screens at market cap $111.9M. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
Not investment advice. Open the LUNG and TECH stock pages for the full models.
Not investment advice.